The extent and wide-ranging consequences of nonadherence has led to considerable research to define and measure adherence, to understand factors that predict nonadherence, and to design and evaluate interventions to improve adherence. In contrast, aspects related to the value of adherence have not been thoroughly debated in the published literature. Inherently, the value of adherence depends upon the perspective taken, that is, patient, clinician, payer, pharmaceutical manufacturer, or society. Certainly, many studies have highlighted the consequences of low adherence across a range of long-term conditions (e.g., Boswell et al. 2012 3 ). However, despite the perceived clinical value, opinions may differ regarding the extent of medication adherence required to attain value. The question that should perhaps be asked is what (and whose) issues need to be considered when thinking about the value of medication adherence?
First, an important question is what should be the appropriate adherence thresholds for different drug classes to meet clinical goals. Generally, 80% and above is considered adherent and less than 80% is usually assumed to be problematic and patients deemed "nonadherent." However, is this assumption correct? For some conditions, the value of 100% adherence may be greater than others as with, for example, the human immunodeficiency virus (HIV), where even relatively small gaps in adherence can lead to the development of drugresistant forms of HIV. The Pharmacy Quality Alliance recommends 90% as the threshold above which patients on antiretroviral drugs for HIV/AIDS should be considered adherent. 7 But for other conditions, the goal of 90% or 100% adherence may not be as critical or reasonable. For example, an asthma patient may be prescribed an antihistamine for allergies that he/she uses daily during the fall and spring, since these are the only problematic seasons for his/her allergies. Upon analyzing this person's health care utilization using the standard medication
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possession ratio (MPR) or proportion of days covered (PDC), it would appear that adherence is 50% at best. However, this patient's treatment regimen is not only rational and reasonable, but 100% adherent with no long-term negative consequences.
Second, as health care researchers, is it correct to assume that patients are unable to make rational judgments of when to take or not take their prescribed medications? Patients may take their medications differently than what is prescribed on the label for various reasons; for example, they experience side effects from the medication, or they have a short-term illness (i.e., a cold or flu) that makes it temporarily difficult to take their medicine as prescribed. Patients with long-term conditions may also know their medications and symptoms so well that they can monitor and manage their medications effectively but would not be considered adherent. Medication regimens can be supplemented by samples from doctors' offices, or patients may supplement with similar over-the-counter products that were once prescription only (i.e., Prilosec for heartburn). Importantly, there are many valid reasons for adherent patients to be less than 80% adherent that are not captured or evaluated when calculating MPRs. Recent research supports the need to recognize the extent of "rational nonadherence" and highlights that a considerable amount of nonadherence can be attributed to intentional behavior and deliberate decision making on the part of the patient. 8 Side effects (real or perceived), cost, perceptions of drug effectiveness, and impact of medication on day-to-day activities can all be seen as rational reasons for not taking a medication as prescribed. [8] [9] [10] Further research is needed to better understand how patients' perceptions and decisions impact the quality and cost of their care. In practice, clinicians can help by acknowledging, understanding, and addressing, where necessary, patients' unique views and ways of taking their medications.
A third issue relates to measuring medication adherence: How can we value adherence when we are not even sure how accurate our measures of adherence are? A wide range of methods have been used to measure medication adherence, such as self-reported questionnaires, pill counts, prescription refills, and electronic-monitoring devices. However, there is no gold standard, which has resulted in a lack of understanding as to which methods are most appropriate to accurately measure medication adherence in research and in clinical practice. [11] [12] There is a tremendous need to develop new methods to measure adherence that will allow health care researchers to more accurately assess adherence to increase its value to all. Accurate assessments of adherence are also critical for the evaluation of
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Coyne is employed by Evidera, which provides consulting and other research services to pharmaceutical, device, government, and nongovernment organizations. As an Evidera employee, she works with a variety of companies and organizations and is expressly prohibited from receiving any payment or honoraria directly from these organizations for services rendered. quality improvement initiatives to improve medication adherence, such as the National Consumers League "Script Your Future" campaign in the United States. 13 In conclusion, with the move towards greater patientcenteredness in research and health care delivery (e.g., with new research agenda setting from the recently formed PatientCentered Outcomes Research Institute [PCORI] in the United States), debating and understanding the value of adherence across different patient populations-and the issue of rational nonadherence-is timely and important. Achieving greater consensus as to the value of adherence has implications for how we define adherence, how we interpret the results of studies that report the extent of nonadherence, how we develop and evaluate interventions to improve medication-taking behavior, and how health care professionals communicate with patients (and document this communication) about adhering to their prescribed medications. Importantly, the patient's perspective must be included in determining the value of adherence.
